Drugs / Montanide
Montanide
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT01489956 | Dec 2011 → Apr 2013 | autoimmune disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT00935545 | Jul 2009 → Jan 2014 | central nervous system neoplasm | NYU Langone Health | Completed | No outcome recorded |
| Phase 1 | NCT00616941 | Mar 2008 → Jun 2011 | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Ludwig Institute for Cancer Research | Completed | No outcome recorded |
| Phase 1 | NCT00124124 | Jul 2005 → Jul 2008 | melanoma | Dr. Nina Bhardwaj | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01079741 | Sep 2010 → Mar 2013 | melanoma | Nina Bhardwaj | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00651703 | Apr 2008 → Dec 2009 | melanoma | Cytos Biotechnology AG | Completed | No outcome recorded |
Also used as a comparator or background therapy in 9 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03929029 Background | Nov 2020 → Dec 2022 overdue | cutaneous melanoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04270149 Background | Sep 2020 → May 2025 overdue | breast cancer | Herbert Lyerly | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02240537 Background | Jan 2015 → Dec 2016 | acute myeloid leukemia, myelodysplastic syndrome, smoldering plasma cell myeloma | Benovus Bio, Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT00112242 Background | Feb 2004 → Mar 2013 | melanoma | Centre Hospitalier Universitaire Vaudois | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT01543464 Background | May 2012 → Sep 2016 | melanoma | Inge Marie Svane | Terminated | No outcome recorded |
| Phase 2 | NCT01265433 Background | Dec 2010 → Nov 2016 | malignant pleural mesothelioma | Sellas Life Sciences Group | Completed | No outcome recorded |
| Phase 2 | NCT00488592 Background | Jun 2007 → Apr 2010 | acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00433745 Background | Feb 2007 → Nov 2009 | acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00665002 Background | Jun 2008 → Jul 2013 | leukemia | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Montanide | “WT1 vaccination (9 doses of WT-1:126-134 peptide (in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim)” NCT00433745 ↗14“Vaccine: 250 microgram IDO5 peptide + 250 microgram Survivin peptide + 500 microL Montanide every 2nd week” NCT01543464 ↗ “ESR1 peptides plus Montanide and GM-CSF” NCT04270149 ↗ |
| Known as | mineral oil, USP | “Drug: Montanide Other Names: mineral oil, USP BB-MPI-03 is emulsified with Montanide and administered intradermally (ID) within 1-2 cm of the 2 sargramostim injection sites 1-3...” NCT02240537 ↗ |
| Known as | Montanide-ISA-51 | “poly-ICLC in Montanide-ISA-51 (Montanide)” PMID 24777970 ↗ Sep 2013 |
| Modality | Other / unclassified | “Montanide adjuvant” NCT00112242 ↗ |
| Route | Subcutaneous | “In this phase I trial, 19 patients received a mean of 8 (range 1-12) monthly vaccines s.c. composed of the long synthetic NY-ESO-179-108 peptide and CpG-B (PF-3512676),...” PMID 27853637 ↗ Sep 2016 |